Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Advances study found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://emilyn753gii2.celticwiki.com/user